NCT04836507View on ClinicalTrials.gov

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

February 29, 2028

Conditions
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal Large B-Cell Lymphoma (PMBCL)High-grade B-cell LymphomaTransformed Follicular Lymphoma (TFL)
Interventions
BIOLOGICAL

CRC01

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Curocell Inc.
All Listed Sponsors
lead

Curocell Inc.

INDUSTRY